

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 November 2005 (10.11.2005)

PCT

(10) International Publication Number
WO 2005/105827 A3

(51) International Patent Classification:

C07K 5/087 (2006.01) **A61K 38/06** (2006.01)
C07K 5/08 (2006.01)**S., Jr.** [US/US]; 753 Orange Street #3, New Haven, CT 06511 (US). **CHABALA, John, Clifford** [US/US]; 602 Sherwood Parkway, Mountainside, NJ 07092 (US).

(21) International Application Number:

PCT/US2005/012740

(74) Agents: **HALSTEAD, David, P.** et al.; Ropes & Gray LLP, One International Place, Boston, MA 02110-2624 (US).

(22) International Filing Date: 14 April 2005 (14.04.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/562,340	15 April 2004 (15.04.2004)	US
60/569,096	7 May 2004 (07.05.2004)	US
60/599,401	6 August 2004 (06.08.2004)	US
60/610,001	14 September 2004 (14.09.2004)	US
60/610,002	14 September 2004 (14.09.2004)	US
60/610,159	14 September 2004 (14.09.2004)	US
60/620,573	20 October 2004 (20.10.2004)	US

(71) Applicant (for all designated States except US): **PROTEOLIX, INC.** [US/US]; 225 Gateway Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SMYTH, Mark, S.** [US/US]; 860 Pollux Court, Foster City, CA 94404 (US). **LAIDIG, Guy, J.** [US/US]; 329 Waverley Street, Menlo Park, CA 94025 (US). **BORCHARDT, Ronald, T.** [US/US]; 3100 Campfire Drive, Lawrence, KS 66049 (US). **BUNIN, Barry, A.** [US/US]; 4171 George Ave #4, San Mateo, CA 94403 (US). **CREWS, Craig, M.** [US/US]; 286 Livingston Street, New Haven, CT 06511 (US). **MUSSER, John, H.** [US/US]; 23 Michael Court, San Carlos, CA 94070 (US). **SCHNEEKLOTH, John,**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:

30 March 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS FOR PROTEASOME ENZYME INHIBITION

(57) Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.



WO 2005/105827 A3